The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc.’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor and ivacaftor) and Kalydeco (ivacaftor) for use in people with cystic fibrosis with certain rare mutations.

Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.